 Watchful Waiting
"Watchful Waiting" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clinical management approach wherein immediate therapy is not provided but there is a period of observation during which periodic tests monitor patient and the progression of the illness. (Driffield T, Smith PC Med Decis Making. 2007 Mar-Apr;27(2):178-88)
| Descriptor ID |
D057832
|
| MeSH Number(s) |
N04.761.559.590.900
|
| Concept/Terms |
Watchful Waiting- Watchful Waiting
- Waiting, Watchful
- Waitings, Watchful
- Watchful Waitings
|
Below are MeSH descriptors whose meaning is more general than "Watchful Waiting".
Below are MeSH descriptors whose meaning is more specific than "Watchful Waiting".
This graph shows the total number of publications written about "Watchful Waiting" by people in this website by year, and whether "Watchful Waiting" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 2 | 2 | | 2012 | 3 | 0 | 3 | | 2013 | 2 | 4 | 6 | | 2014 | 4 | 2 | 6 | | 2015 | 3 | 4 | 7 | | 2016 | 2 | 1 | 3 | | 2017 | 2 | 1 | 3 | | 2018 | 1 | 4 | 5 | | 2019 | 1 | 3 | 4 | | 2020 | 1 | 0 | 1 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Watchful Waiting" by people in Profiles.
-
Ayoub F, Davis AM, Chapman CG. Pancreatic Cysts-An Overview and Summary of Society Guidelines, 2021. JAMA. 2021 Jan 26; 325(4):391-392.
-
Parsons JK, Zahrieh D, Mohler JL, Paskett E, Hansel DE, Kibel AS, Liu H, Seisler DK, Natarajan L, White M, Hahn O, Taylor J, Hartman SJ, Stroup SP, Van Veldhuizen P, Hall L, Small EJ, Morris MJ, Pierce JP, Marshall J. Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):140-148.
-
Weinstock C, Suzman D, Kluetz P, Baxley J, Viviano C, Ibrahim A, Jarow J, Sridhara R, Liu K, Carroll P, Eggener S, Hu JC, Hussain M, King M, Klein E, Kungel T, Makarov D, Pinto PA, Rini B, Roach M, Sandler H, Schlegel PN, Song D, Goldberg K, Pazdur R, Beaver JA. Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. J Urol. 2020 01; 203(1):115-119.
-
Newman NB, Brett CL, Kluwe CA, Patel CG, Attia A, Osmundson EC, Kachnic LA. Immortal Time Bias in National Cancer Database Studies. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):5-12.
-
Yushak M, Mehnert J, Luke J, Poklepovic A. Approaches to High-Risk Resected Stage II and III Melanoma. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e207-e211.
-
Werntz RP, Eggener SE. Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015. Eur Urol. 2019 08; 76(2):252.
-
Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB, Zheng SL, Isaacs WB, Xu J. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. Eur Urol. 2019 05; 75(5):743-749.
-
Weiner AB, Schaeffer EM, Eggener SE. "Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. Eur Urol. 2018 12; 74(6):708-709.
-
Modi PK, Kaufman SR, Qi J, Lane BR, Cher ML, Miller DC, Hollenbeck BK, Shahinian VB, Dupree JM. National Trends in Active Surveillance for Prostate Cancer: Validation of Medicare Claims-based Algorithms. Urology. 2018 Oct; 120:96-102.
-
Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer. 2018 04 02; 18(1):359.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|